Celsion (CLSN) Stock Rating Lowered by ValuEngine

Celsion (NASDAQ:CLSN) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Oppenheimer initiated coverage on Celsion in a report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Celsion currently has an average rating of “Buy” and an average target price of $11.90.

Celsion (CLSN) opened at $2.58 on Thursday. The firm has a market capitalization of $45.40, a price-to-earnings ratio of -0.44 and a beta of 1.80. Celsion has a fifty-two week low of $1.24 and a fifty-two week high of $6.06.

A hedge fund recently bought a new stake in Celsion stock. Virtu Financial LLC purchased a new position in shares of Celsion Co. (NASDAQ:CLSN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned approximately 0.24% of Celsion as of its most recent filing with the SEC. Hedge funds and other institutional investors own 3.84% of the company’s stock.

WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/17/celsion-clsn-stock-rating-lowered-by-valuengine.html.

About Celsion

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply